Addendum
Daratumumab (newly diagnosed multiple myeloma, ineligible for stem cell transplant) – Addendum to Project A25-108
Report documents
-
Addendum
Daratumumab (newly diagnosed multiple myeloma, ineligible for stem cell transplant) – Addendum to Project A25-108
Dossier assessment
Indication:
Adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant
Result of dossier assessment:
After addendum now: hint of minor added benefit
Additional information
Federal Joint Committee (G-BA)
19-02-2026 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A26-02
- Commission
- Commission awarded on 13.01.2026 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A26-02_en
Connected Projects
-
Dossier assessment
Daratumumab (newly diagnosed multiple myeloma, ineligible for stem cell transplant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed